Skip to main content
Premium Trial:

Request an Annual Quote

Study Suggests BG's Galectin-3 Test Useful in Predicting Hospital Readmissions and Cardiac Events


BG Medicine this week announced the publication of a multicenter clinical trial that found that the company's BGM Galectin-3 test was useful in predicting unplanned hospital readmissions and fatal events in heart failure patients.

The study, which was detailed in a paper published this month in the International Journal of Cardiology, followed 419 heart failure patients from four Spanish hospitals over a 12-month period and found that including galectin-3 testing in hospital discharge risk assessments identified elevated risk in roughly 25 percent of patients who would have otherwise been categorized as low risk.

The study also found that heart failure patients with elevated galectin-3 levels had an 84 percent higher chance of experiencing hospital readmission or a fatal event than patients with lower levels.

Hospital readmissions have become a key focus for BG Medicine's commercialization plans for the BGM Galectin-3 test. The company shifted toward this application last year in response to new guidelines implemented by the US Centers for Medicare and Medicaid Services that penalize hospitals with high patient readmission rates. The IJC study follows two studies the company published in March that indicated that serial evaluation of galectin-3 levels could help clinicians identify heart failure patients at increased risk of unplanned hospital readmissions.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.